United Therapeutics Corporation
$ 553.14
1.55%
09 Jun - close price
- Market Cap 23,478,987,000 USD
- Current Price $ 553.14
- High / Low $ 554.48 / 544.00
- Stock P/E 20.43
- Book Value 139.98
- EPS 27.07
- Next Earning Report 2026-07-29
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA 0.13 %
- ROE 0.20 %
- 52 Week High 609.35
- 52 Week Low 272.12
About
United Therapeutics Corporation, a biotechnology company, is dedicated to the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company is headquartered in Silver Spring, Maryland.
Analyst Target Price
$665.23
Quarterly Earnings
| Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2026-05-06 | 2026-02-25 | 2025-10-29 | 2025-07-30 | 2025-04-30 | 2025-02-26 | 2024-10-30 | 2024-07-31 | 2024-05-01 | 2024-02-21 | 2023-11-01 | 2023-08-02 |
| Reported EPS | 5.82 | 7.7 | 7.16 | 6.41 | 6.63 | 6.19 | 6.39 | 5.85 | 6.17 | 4.36 | 5.38 | 5.24 |
| Estimated EPS | 6.86 | 7.1 | 6.96 | 6.94 | 6.54 | 6.2668 | 6.42 | 6.41 | 5.66 | 4.19 | 5.04 | 4.78 |
| Surprise | -1.04 | 0.6 | 0.2 | -0.53 | 0.09 | -0.0768 | -0.03 | -0.56 | 0.51 | 0.17 | 0.34 | 0.46 |
| Surprise Percentage | -15.1603% | 8.4507% | 2.8736% | -7.6369% | 1.3761% | -1.2255% | -0.4673% | -8.7363% | 9.0106% | 4.0573% | 6.746% | 9.6234% |
Next Quarterly Earnings
| Jun 2026 | |
|---|---|
| Reported Date | 2026-07-29 |
| Fiscal Date Ending | 2026-06-30 |
| Estimated EPS | 6.84 |
| Currency | USD |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: UTHR
2026-06-04 21:10:05
Paul A. Mahon, EVP and General Counsel at United Therapeutics Corp, sold 8,300 shares for $4.54 million on June 4, 2026, following the exercise of stock options. This sale was part of a pre-arranged trading plan, leaving Mahon with 45,172 shares directly held. The transactions occurred while UTHR shares traded near their 52-week high, after a significant 69.61% gain over the past year.
2026-06-04 05:40:45
This article provides an analysis of United Therapeutics Corp (UTHR) financials, detailing its revenue breakdown, profitability margins, and a comparison with competitors. Tyvaso DPI is identified as the largest revenue contributor. The company boasts strong gross, operating, and net margins, along with a solid Return on Equity, showcasing its efficiency and market position within the Pharmaceuticals industry.
2026-06-03 09:09:38
Martine A. Rothblatt, CEO of United Therapeutics Corp, sold 1,500 shares of company stock for $863,947 on May 26, 2026. This transaction was part of a pre-arranged 10b5-1 trading plan involving the exercise of stock options. Following the sale, Rothblatt directly holds 43,153 shares.
2026-06-02 21:04:22
United Therapeutics CFO James Edgemond sold 10,000 shares of the company's common stock for approximately $5.48 million on June 1, 2026, as part of a pre-arranged trading plan. On the same day, he acquired 10,000 shares through stock option exercise totaling $1.18 million. The company's stock has seen strong performance, and recent news includes positive phase 3 study results for nebulized Tyvaso, a partnership with Varda Space Industries, and mixed Q1 financial results.
2026-06-02 21:04:22
Martine A. Rothblatt, CEO of United Therapeutics Corp, sold 1,500 shares totaling $863,947 on May 26, 2026, under a pre-arranged trading plan. This transaction is part of a larger plan involving the exercise of stock options expiring in 2027. The company recently announced positive phase 3 study results for its TETON-1 study and has partnered with Varda Space Industries to explore microgravity-based pharmaceutical processing.
2026-06-02 21:04:22
United Therapeutics CEO Martine Rothblatt sold approximately $5.21 million worth of company common stock on June 1, 2026, after exercising stock options. The transactions were conducted under a pre-arranged 10b5-1 trading plan. Despite recent insider sales and first-quarter revenue falling short of expectations, United Therapeutics shares have seen a strong 67% return over the past year, and analysts like TD Cowen maintain a "Buy" rating, citing positive clinical developments for its product, Tyvaso.
